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Abstract
Objectives Cardiomyopathy is a common complication of mi-
tochondrial disorders, associated with increased mortality.
Two dimensional speckle tracking echocardiography
(2DSTE) can be used to quantify myocardial deformation.
Here, we aimed to determine the usefulness of 2DSTE in
detecting and monitoring subtle changes in myocardial dys-
function in carriers of the 3243A>G mutation in mitochondri-
al DNA.
Methods In this retrospective pilot study, 30 symptomatic and
asymptomatic carriers of the mitochondrial 3243A>G muta-
tion of whom two subsequent echocardiograms were available
were included.Wemeasured longitudinal, circumferential and
radial strain using 2DSTE. Results were compared to pub-
lished reference values.
Results Speckle tracking was feasible in 90 % of the patients
for longitudinal strain. Circumferential and radial strain
showed low face validity (low number of images with suffi-
cient quality; suboptimal tracking) and were therefore rejected
for further analysis. Global longitudinal strain showed good
face validity, and was abnormal in 56–70 % (depending on
reference values used) of the carriers (n = 27). Reproducibility
was good (mean difference of 0.83 for inter- and 0.40 for intra-
rater reproducibility; ICC 0.78 and 0.89, respectively). The
difference between the first and the second measurement
exceeded the measurement variance in 39 % of the cases
(n = 23; feasibility of follow-up 77 %).
Discussion Even in data collected as part of clinical care, two-
dimensional strain echocardiography seems a feasible method
to detect and monitor subtle changes in longitudinal myocar-
dial deformation in adult carriers of the mitochondrial
3243A>G mutation. Based on our data and the reported accu-
racy of global longitudinal strain in other studies, we suggest
the use of global longitudinal strain in a prospective follow-up
or intervention study.
Abbreviations
2DSTE 2-dimensional speckle tracking
echocardiography
4-CV 4 chamber view
95%CI 95 % confidence interval
cMRI Cardiac magnetic resonance imaging
DM Diabetes mellitus
EF Ejection fraction
FS Fractional shortening
GLS Global longitudinal strain
IQR Inter quartile range
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Introduction
Cardiomyopathy is a common complication of mitochondrial
disorders, with a prevalence up to 14 % in adults (Arpa et al.
2003) and 58 % in children (Holmgren et al. 2003; Scaglia
et al. 2004). The presence of cardiomyopathy has been asso-
ciated with increased mortality in both children and adults
(Holmgren et al. 2003; Scaglia et al. 2004; Majamaa-Voltti
et al. 2008; Malfatti et al. 2013). In carriers of the
m.3243A>G mutation, one of the most common genetic
causes of mitochondrial disease. Reference chinnery, the prev-
alence of either symptomatic or asymptomatic cardiomyopa-
thy ranges from 18 to 56 %, depending on the population
studied and the method used (Majamaa-Voltti et al. 2002;
Vydt et al. 2007; Malfatti et al. 2013). Cardiomyopathy asso-
ciated with this mutation was characterized by concentric left
ventricle hypertrophy (Majamaa-Voltti et al. 2002; Bates et al.
2013a, b) with progressive dilation and decreased systolic
function, developing over several years (Okajima et al.
1998). Some (but not all) of these small studies, reported a
higher incidence of cardiac involvement in severe disease and
patients with a high heteroplasmy percentage (Majamaa-Voltti
et al. 2002; Vydt et al. 2007; Hollingsworth et al. 2012).
The m.3243A>G mutation is a mitochondrial DNA muta-
tion and therefore follows maternal inheritance (Smeitink
et al. 2006). To understand the importance of this study, the
following aspects have to be considered: i) the mutation is
presen t in a var iab le percentage of a l l mtDNA
(heteroplasmy); ii) virtually all organs may be affected in var-
ious different patterns; and iii) this is not only dependent on
the heteroplasmy percentage of the mutation.
The severity of the myocardial dysfunction is usually
assessed by conventional echocardiography and tagged cardi-
ac magnetic resonance imaging (cMRI). Previously, tagged
cMRI showed abnormal myocardial deformation in 22
asymptomatic m.3243A>G carriers (Bates et al. 2013a, b).
cMRI is used as a reference standard for myocardial deforma-
tion, but it is a time-consuming and expensive procedure
which requires dedicated expertise. Therefore, this method is
less feasible as bed side modality in multi-centre trials.
Conventional echocardiography, in contrast, is widely avail-
able, but has low sensitivity in detecting subtle and regional
changes in myocardial function (Aurigemma et al. 1995). The
off-line processing of conventional echocardiograms using
two dimensional speckle tracking echocardiography
(2DSTE) software enables more sensitive quantification of
the global and regional myocardial deformation (Artis et al.
2008). This software tracks myocardial ‘speckle’ patterns
throughout the myocardial cycle, facilitating calculation of
myocardial deformation or strain in three directions (longitu-
dinal, radial and circumferential). The technique is reliable
(Mavinkurve-Groothuis et al. 2009) and accurate
(Amundsen et al. 2006; Choi et al. 2013) and is able to detect
subtle changes in myocardial function at an early stage, even
before decrease in conventional echocardiographic parameters
(e.g. ejection fraction and shortening fraction) is observed
(Poterucha et al. 2012). Recently, global longitudinal strain,
known as the most reliable component of strain analysis
(Kocabay et al. 2014), was incorporated into the recommen-
dations for multimodality imaging evaluation and monitoring
of cardiac (dys)function of adult patients during and after can-
cer therapy (Plana et al. 2014). A 10 % decrease in the longi-
tudinal strain is a significant outcome measure for chemother-
apy induced cardiomyopathy.
In this retrospective pilot study we evaluate the usefulness
and feasibility of 2DSTE in detecting and monitoring subtle
changes in myocardial deformation in adult carriers of the
m.3243A>G mutation with a wide spectrum of clinical dis-
ease severity, since 2DSTEmight be a potential outcome mea-
sure to evaluate responsiveness to future therapy for this
disease.
Methods
Study population
All subjects were identified from our BNational inventory of
patients with the m.3243A>Gmutation^ study, including both
symptomatic and asymptomatic carriers (de Laat et al. 2012).
Subjects with a detectable heteroplasmy percentage (detection
limit ≥5%) in either buccal mucosa cells, leukocytes, or uri-
nary epithelial cells (UEC) are considered to be carriers of the
mutation. As part of usual clinical care, both symptomatic and
asymptomatic carriers undergo cardiac ultrasound (approxi-
mately two-yearly in asymptomatic individuals; more fre-
quently if clinically indicated). Carriers of the m.3243A>G
mutation of whom two subsequent echocardiograms were
available were included in this study. Only part of these pa-
tients were included in our previously published study on
biomarkers (Koene et al. 2015).
Clinical assessment protocol
The clinical assessment at the time of the echocardiogram
included the carrier’s medical history, current cardiac com-
plaints and the use of medication, physical examination
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(including blood pressure, height and weight) and an electro-
cardiogram (ECG).
In the context of the BNational inventory of patients with
the m.3243A>G mutation^, patients and their maternal rela-
tives undergo several investigations including the assessment
of general mitochondrial disease severity using the Newcastle
Mitochondrial Disease Adult Scale (NMDAS) (Phoenix et al.
2006). The NMDAS score closest in time to the echocardiog-
raphy was reported. The NMDAS contains the following four
domains: i) current function; ii) system specific involvement;
iii) current clinical assessment; and iv) quality of life. In our
analysis, we used domains i-iii to calculate disease severity.
Severe mitochondrial disease was defined previously as an
NMDAS score above 20 (de Laat et al. 2012). We defined
asymptomatic disease as an NMDAS = 0; mild mitochondrial
disease as an NMDAS score of 1 through 5 and moderate
mitochondrial disease as an NMDAS score of 6 through 20
(Koene et al. 2014). The presence and severity of diabetes
mellitus (DM) and cardiovascular involvement was also ob-
tained from the NMDAS (Schaefer et al. 2006). Quality of
life, with sub-scores for mental and physical quality of life,
was determined using a Dutch translation of the SF-12v2 and
American reference values SFv12 ref. The quality of life can
vary from 0 to 70 for both mental and physical health, where
50 is the population’s mean (standard deviation 10).
Subjective change during follow-up was part of the general
history taking of the cardiologist.
Laboratory investigations (+/− 6 months) were reported.
Carriers were classified as having decreased creatinine clear-
ance only, microalbuminuria only, both or neither.
Microalbuminuria was defined as an albumin-to-creatine-
ratio of >2.0 g/mol for men and >2.5 g/mol for women.
Decreased creatinine clearance was defined as a glomerular
filtration rate <60 ml/min/1.73 m2.
Echocardiography
All carriers underwent a transthoracic 2D echocardiogram in
supine and lateral position at rest. The echocardiogram was
performed as part of our regular patient care, using a standard-
ized echocardiographic protocol published previously (Bulten
et al.2014), by an experienced echocardiography technician
and supervised by experienced cardiologist (JT). Images were
obtained with an M3S transducer using the Vivid 7 and M5S
transducer using Vivid E9 echographic scanners (GE,
Vingmed Ultrasound, Horten, Norway). Quantification of car-
diac chamber size, left ventricular mass and systolic and dia-
stolic left ventricular function were performed in accordance
with the recommendations for chamber quantification by the
American Society of Echocardiography’s Guidelines and
Standard Committee and the Chamber Quantification
Writing Group (Lang et al. 2005; Nagueh et al. 2009), as
previously described (Bulten et al. 2014). In case the ejection
fraction (EF) was not available, fractional shortening (FS) was
used.
Strain analysis was done according to our previously pub-
lished protocol (Mavinkurve-Groothuis et al. 2009) by an ex-
perienced investigator (LK), using two-dimensional grey
scale images taken in the parasternal apical 4-chamber view
(4-CV) and at mid-cavity short-axis view (at the level of the
papillary muscle; SAX-PM). The investigator was not aware
of the clinical condition and medical treatment of the patients.
A sector scan angle of 30–60° was chosen and frame rates of
70 Hz or more were used (Leitman et al. 2004). Cine loops of
preferably three cardiac cycles triggered by the R wave of the
QRS complex were digitally saved. Offline analysis was per-
formed using software for echocardiographic quantification
(EchoPAC 6.1.0, GE Medical Systems, Horten, Norway).
Timing of aortic valve closure and mitral valve opening was
used to indicate end-systole and start of diastole respectively.
Manual tracking of the endomyocardial borders was per-
formed at the end-systolic frame. An automatic generation
of the second epicardial tracing was created by the software,
which also automatically divided the LV myocardium into six
equal segments, which were named and localized according to
the statement of the Cardiac Imaging Committee of the
Council on Clinical Cardiology of the American Heart
Association (Cerqueira et al. 2002; Voigt et al. 2015).
Quality of the speckle tracking was verified for each segment
and adjusted when needed. Tracking was only accepted if
visual inspection indicated adequate tracking over the full car-
diac cycle. Preferably, three cardiac cycles were analysed for
each segment and exported as text files for further post-pro-
cessing. As a next step the exported strain curves were post-
processed, in a custom made software package using Matlab
(r2013b), in order to estimate the average strain curve and to
obtain the final strain parameters out of this data (Mavinkurve-
Groothuis et al. 2009). Figure 1 shows a composite figure with
the region of interest (left side) and graphic depiction of lon-
gitudinal strain in 4-chamber long axis view.
To evaluate the conventional echocardiographic values ob-
tained in our patient group, we used the reference values de-
scribed by the American Society of Echocardiography (Lang
et al. 2005; Nagueh et al. 2009). Strain values are dimension-
less and are expressed in percentages (Berne and Levy 1993).
Global longitudinal myocardial strain (GLS) was calculated
by averaging the six segments of three cardiac cycles using the
apical 4-chamber view (4-CV). Global radial and circumfer-
ential myocardial strain (GRS and GCS, respectively) were
calculated by averaging the six of three cardiac cycles seg-
ments of the mid-cavity short-axis view (SAX-PM). When
less than four segments were available for averaging, global
strain was not calculated. Age-matched reference values for
end-systolic strain were obtained from Kocabay et al.
(Kocabay et al. 2014) and from Kuznetsova et al.
(Kuznetsova et al. 2008). Values were considered abnormal
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when deviating >2 standard deviations (SD) from mean
(Kocabay) or < P5 or > P95 (Kuznetsova, SDs were not re-
ported). Our group (LK, CdK, GW) has published multiple
studies on myocardial strain in both children and adults
(Marcus et al. 2011; Mavinkurve-Groothuis et al. 2013;
Bulten et al. 2014). A recent meta-analysis shows that the
LV GLS reference values for children obtained by our group
are well within the averaged 95 % CI (Levy et al. 2015). Each
carrier was compared individually to his/her age-matched ref-
erence values. Changes were reported as absolute numbers
and changes of ≥ 10 % were accepted as real changes, as this
number exceeds the coefficient of variation reported in litera-
ture (Mele et al. 2015) recommended by Plana et al.
Reproducibility studies
Ten images in which strain analysis was possible were ran-
domly selected by a physician not involved in the strain mea-
surements for reproducibility studies. To determine inter-
observer reproducibility, longitudinal strain was analysed by
another experienced rater (GW), blinded to previous results.
Intra-rater reproducibility was determined by rating the same
images, more than 6 months later. For both inter- and intra-
observer reproducibility, absolute differences and the
intraclass correlation coefficients were calculated.
Follow-up study
Only carriers of whom two echocardiograms in which GLS
analysis was feasible were available and were included in the
follow-up study. Subjective and objective changes in clinical
status, changes in the use of medication and changes in con-
ventional parameters were assessed during follow-up. Since
all echocardiograms were performed as part of clinical care,
the time between two examinations is variable.
Medical ethical approval
This study is part of the BNational Inventory of Patients with
the m.3243A>G mutation^, which was approved by the re-
gional Medical Research Ethics Committee. In accordance
with the Helsinki agreement, written informed consent was
obtained from each participant.
Statistical analysis
The absolute difference was calculated by subtracting the first
measurement from the second measurement. All variables
were assessed for (log)normality. To prevent non-real values
for zero values of the NMDAS including its sub domains and
symptom specific items, these values were increased by 1
prior to elog transformation. Variables with a (log)normal dis-
tribution, were compared using parametric tests, and the mean
and 95 %-confidence intervals (95 % CIs) are reported.
Variables that deviated strongly from a (log)normal distribu-
tion (based on skewness/kurtosis) were analysed by
performing a non-parametric test and the median and inter-
quartile ranges (IQRs) are reported. Inter- and intra-rater reli-
ability were calculated using intraclass correlation coefficients
for absolute agreement (ICC). Outliers were not excluded
from any of the analyses and missing data were not replaced.
In case a high number of tests were performed (5 or more),
critical P-values were adjusted using the Bonferroni method
(i.e. 0.05/n where n = number of tests). Correlation coeffi-
cients were interpreted in accordance with the guidelines pro-
vided at the BMJ website (http://www.bmj.com/about-
Fig. 1 Two-dimensional strain measurement. Two-dimensional strain
measurement in longitudinal plane. At the left top, the region of interest
is shown, at the right the graphic depicture of the transmural strain in a
young female m.3243A>G carrier who was found to have severe cardio-
myopathy in 2010. After diagnosis, she was started on medication (di-
uretics, ACE inhibitor and β blocker) and underwent an intensive heart
failure rehabilitation programme. At the echocardiogram in 2013, she
reported a highly significant increase in exercise tolerance. The coloured
lines represent the measurements of regional deformation of the individ-
ual regions, the dotted line represents their average (global strain),
analysed by GE EchoPac. GLS increased from −12.7 to −19.6
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bmj/resources-readers/publications/statistics-square-one/11-
correlation-and-regression; consulted 29-June-2015).
All analyses were performed using IBM’s SPSS statistics
software packages, version 20.0.0.1.
Results
Carrier description
The study algorithm is presented in Fig. 2. Thirty carriers of
the m.3243A>G mutation of whom two subsequent echocar-
diograms were available for 2D strain analysis were included
in this study (Table 1). Nineteen of these carriers were female;
five of them were current smokers. Eighteen carriers had dia-
betes mellitus, six microalbuminuria, one decreased creatinine
clearance and ten carriers had cardiovascular involvement ac-
cording to the NMDAS.
In the BNational Inventory of Patients with the m.3243A>G
mutation^, 80 adult carriers had been included before 2012
(since the regular follow-up time is 2 years, we do not account
for carriers included before 2012). For a variety of reasons (e.g.
only one echocardiogram available or echocardiogram made
using a wrong echocardiograph device), only data of 30 carriers
(38 %) from 20 families could be analysed (1–3 family mem-
bers per family). These 30 carriers were not different compared
to the total cohort with respect to their total NMDAS score
(P = 0.35), nor in their sub scores for diabetes mellitus or car-
diovascular disease (P = 0.37 and 0.81 respectively; indepen-
dent samples t-test). BMIwas significantly higher in the includ-
ed carriers compared to the other carriers (P = 0.0062).
Conventional echocardiography at baseline
Table 2 presents the echocardiographic parameters of our
patients. Although the measurement of cardiac chamber
size, left ventricular mass and systolic and diastolic left
ventricular function was feasible in 80–100 % of the pa-
tients, measuring EF was only feasible in 33 % of the
patients. Using conventional echocardiography, seven car-
riers (23 %) did not present with (sub-clinical) cardiac ab-
normalities. Hypertrophy was reported in 40 % of the car-
riers, mild mitral insufficiency in 13 % and mild aortic
insufficiency in 27 % of the carriers.
We found no statistically significant correlation between left
ventricular mass index and the NMDAS (ρ(NMDAS) = 0.01,
P = 0.97; n = 24) and hete roplasmy percentages
(ρ(heteroplasmy UEC) = −0.01; P = 0.97; ρ(heteroplasmy
leucocytes) −0.04, P = 0.87; n = 24).
Strain feasibility
For the analysis of GLS on the 4-CV images, three patients
(10 %) had to be excluded because no GLS analysis could be
Fig. 2 Study algorithm
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performed. Two instead of three cycles were suitable for anal-
ysis in 33 % (e.g. bad quality of the images, only two cardiac
cycles recorded). The assessment of GLS was feasible in 151
(94 %) of the 161 segments available for analysis. During
follow-up; two subsequent images could be analysed in 23
patients (feasibility 77 %).
Table 1 Carrier characteristics. Clinical features of the included
carriers compared to all adult carriers in the BNational inventory of
carriers with the m.3243A>G mutation^. The presence of diabetes
mellitus was obtained from the NMDAS scale (score on diabetes
mellitus item ≥3); the presence of cardiovascular involvement was
obtained from the NMDAS scale (score on cardiomyopathy ≥ 1). P-
values (significance (P < 0.0045)) for the difference at baseline between
this cohort and all adult carriers included before 2012 were calculated
n = Mean (range) Total number of
patients
Difference from total
cohort of carriers (n = 80) p
=
Gender Female 19 30
Age 45.2 (16.7–64.5) 30 0.90
BMI (kg/m2) 23.8 (17.3–34.0) 30 0.006
Alcohol Use 6 27
Abuse 1 27
Smoking Current 5 27
Stopped 5 27
Renal abnormalities Micro-albuminuria 6 30
Decreased creatinine
clearance
1 30
Diabetes mellitus (NMDAS) Yes 18 30 0.37
HbA1c (mmol/mol) 6.7 (5–9.7) 28
Cardiovascular involvement
(NMDAS)
Yes 10 30 0.84
Systolic blood pressure 127 (95–167) 23
<120 mmgHg 5
120–140 mmHg 13
>140 mmHg 5
Diastolic blood pressure (mmHg) 79 (58–98) 23
Total cholesterol (mmol/l) 4.8a (3.5–9.2) 23
HDL cholesterol (mmol/l) 1.1 (0.6–1.9) 21
LDL cholesterol (mmol/l) 2.9 (0.9–4.8) 21
Heteroplasmy in leucocytes (%) 28 (3–73) 30
Heteroplasmy in UEC (%) 52 (7–96) 30
NMDAS 18.6 (0–49) 30 0.35
Domain 1 7.5 (0–21) 30 0.11
Domain 2 7.3 (0–18) 30 0.20
Domain 3 2.6b (0–13) 30 0.96
QoL mental 46 (25–59) 28 0.34
QoL physical 40 (21–58) 28 0.09
Medicationc β blocker 6 30
Calcium channel blocker 1 30
ACE inhibitor 6 30
Angiotensin II blocker 2 30
Insulin 5 30
BMI body mass index; domain 1 current function; domain 2 system specific involvement; domain 3 current clinical assessment; IQR interquartile range;
n number of carriers of which data were available at that specific time point; NMDAS newcastle mitochondrial disease adult scale; QoL quality of life;
UEC urinary epithelial cells
a median is given instead of mean
b lognormal distribution
c not mutually exclusive
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For the SAX-PM view, 18 patients (30 %) had to be ex-
cluded because of low image quality. Only 57 % of the seg-
ments had sufficient image quality to perform radial and cir-
cumferential strain analyses. Because of the low number of
high-quality images, the suboptimal tracking performance of
some specific segments (mainly posterior and lateral) even in
the high-quality images, and the current debate on the repro-
ducibility of radial strain, (Koopman et al. 2010) we chose not
to further process these results and concentrate only on the
longitudinal 2D strain.
Longitudinal 2D strain at baseline
When comparing our results to the age-matched reference
values of Kocabay et al., 15 carriers (56 %) had abnormal
GLS (Table 3).When comparing to the age-matched reference
values of Kuznetsova, 19 carriers (70 %) had abnormal GLS.
Of the seven carriers with normal cardiac function and diam-
eters assessed by conventional echocardiography, two or four
(depending on the reference values used) had abnormal GLS.
In the ten carriers with low fractional shortening, five had low
GLS (one GLS not available). In the nine carriers with a high
diastolic left ventricular posterior wall thickness, seven had
decreased GLS.
No significant correlation between age and GLS was found
(r = −0.21; P = 0.30). GLS was not significantly lower in car-
riers with DM (P = 0.68). GLS was not significantly lower in
carriers with a score 0 versus ≥1 on the cardiovascular in-
volvement item in the NMDAS (P = 0.10). There was no cor-
relation between IVSd and GLS (ρ = 0.35, (P = 0.08). Carriers
with renal abnormalities (including microalbuminuria) did not
have significantly lower GLS compared to carriers without
renal abnormalities (P = 0.65).
GLS correlated significantly to the heteroplasmy percentage
in UEC, but not to heteroplasmy percentage in leucocytes (r =
0.45, P = 0.05 and r = −0.17, P = 0.36, respectively; Fig. 3). No
significant correlation between the NMDAS score and GLS
was found (r = 0.29, P = 0.17). The score in the first, subjective
domain of the NMDAS did not correlate significantly to GLS
(r = 0.18, P = 0.41). There was no significant difference in the
GLS between carriers with asymptomatic, mild, moderate and
severe general mitochondrial disease severity (P = 0.65).
Physical quality of life did not correlate significantly to GLS
(r = 0.18, P = 0.38). No significant correlation between mental
quality of life and GLS was found (r = 0.15, P = 0.49).
Inter- and intrarater reliability
The ICC of inter-rater reliability was 0.78, with a mean differ-
ence of 0.83 (95 % CI 0.38–1.85). The ICC of intra-rater
reliability was 0.89, with a mean difference of 0.40 (95 %
CI 0.11–1.42).
Follow-up
The (changes in) conventional echocardiographic parameters
and GLS for each individual patient are shown in
Supplementary Table 1. Twenty-three patients were suitable
for the analysis of changes in myocardial deformation during
follow-up (feasibility 77 %). Table 4 shows the changes in
GLS, the subjective changes in exercise tolerance and changes
in medications. The median time between the first and the
Table 2 Cardiac characteristics at baseline. Conventional
echocardiographic and myocardial deformation in m.3243A>G carriers
compared to the reference population. Reference values were obtained
fromNagueh et al. and Lang et al. for the conventional echocardiographic
parameters and from Kocabay et al. and Kuznetsova et al. for strain data.
High (>+2SD) and low (−2SD) are based on age-matched reference
values
Median (spread) High values (n (%)) Low values (n (%)) n =
FS (%) 36 (11–56) 2 (7 %) 10 (33 %) 30
EF (%) 64 (25–68) – 3 (30 %) 10
Interventricular septum thickness in diatsole (cm) 0.9 (0.6–3.0) 12 (41 %) – 29
LV posterior wall thickness (cm) 0.9 (0.7–1.4) 13 (45 %) – 29
LV internal diameter in diastole (cm) 4.4 (1.9–6.0) 1 (3 %) 6 (21 %) 29
Mitral valve E/A ratio 1.1 (0.7–4.0) 2 (7 %) 1 (3 %) 29
LV performance (Tei) index 0.4 (0.3–0.8) 11 (41 %) – 27
Isovolumic relaxation time (ms) 84 (50–120) 9 (32 %) 2 (7 %) 28
Pulmonary vein S/D ratio 1.4 (0.54–2.2) 5 (21 %) – 24
Left ventricular mass index (g/m2) 76 (23–140) 4 (17 %) 2 (8 %) 24
Global longitudinal strain compared to Kocabay et al. −16.3 (−7.9–−20.7) − 15 (56 %) 27
compared to Kuzenetsova et al. − 19 (70 %) 27
E/A ratio ratio between early (E) and late (A) filling velocity, measured at the mitral valve; LV left ventricular; S/D ratio ratio between the velocity of the
flow in systole and diastole, ¤ not mutually exclusive
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second echocardiogram was 2.0 years (IQR 1.1–2.7 years;
range 0.5–4.6 years). The disease severity (including the car-
diovascular and diabetes mellitus score and sub domains) as
well as the quality of life did not change significantly during
follow-up (P = 0.11–0.92).
Nine carriers (39 %) had a change in GLS ≥10 % at end
systole. The change in GLS ranged from −7.1 to +6.9 (mean
0.33; 95%CI −5.5–+2.3), where a higher (thus positive) value
represents an improvement in longitudinal strain.
Examples of the difference in responsiveness of myocardi-
al strain include two cases of young carriers with m.3243A>G
related cardiomyopathy which were documented in more de-
tail: one young woman with a generally mild phenotype and
newly discovered severe heart failure at the first echocardio-
gram recovered very well under pharmacotherapy and reha-
bilitation (GLS −12.7 to −19.6), while a male carrier with
MELAS syndrome had a stable, severe heart failure (GLS
−7.9 to −5.4). See Fig. 1 for the first case.
Discussion
The aim of this retrospective pilot study was to evaluate the
value and feasibility of 2DSTE in detecting and monitoring
myocardial dysfunction in both symptomatic and asymptom-
atic carriers of the m.3243A>G mutation. Even when data
Table 3 Global strain in carriers individually compared to age-matched
controls. Global longitudinal end-systolic strain in m.3243A>G com-
pared to the age-matched reference population (n = 27). tThe low values
(under −2 SD for age-matched reference values) are marked in red, the
values below the mean (between 0 and −2 SD) are marked in orange. The
high values (above +2 SD) are marked in green
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F 30 42 ND 16 18 6 1 0,7 4 -12,7 -12,7
F 31 49 57 13 11 1,9 0,9 1,3 0,99 -12,8 -12,8
M 43 19 ND 7 20 3,9 1 1 0,8 -13,1 -13,1
F 47 31 61 43 17 4,4 0,9 0,8 1,26 -13,2 -13,2
F 58 17 41 21 37 63 3,8 1,3 1,8 1,49 -13,9 -13,9
F 38 23 30 21 44 4,4 1,2 1,4 -13,9 -13,9
M 51 16 78 16 51 4,4 1,3 1,4 0,91 -14,1 -14,1
F 57 25 85 15 49 3,5 1,1 1 0,75 -14,2 -14,2
F 49 17 45 38 33 67 3,8 1,4 1,3 0,86 -14,3 -14,3
M 39 30 54 11 43 5,6 0,9 1 1,44 -16,1 -16,1
F 28 27 67 8 27 66 4,8 0,9 0,9 0,71 -16,1 -16,1
F 60 6 30 26 40 4,6 1 1 1,01 -16,9 -16,9
M 54 6 77 15 30 4,5 0,9 1 1,16 -17,1 -17,1
F 26 34 86 0 30 66 4,4 0,9 0,8 2,22 -17,1 -17,1
F 56 10 27 26 24 4,5 0,9 0,9 0,73 -17,6 -17,6
F 46 19 44 21 15 48 4 0,9 0,6 0,89 -17,7 -17,7
M 17 19 58 0 37 5,3 0,8 0,8 1,97 -17,7 -17,7
M 40 17 84 7 4,5 0,9 0,8 1,62 -18,3 -18,3
M 61 16 79 20 37 4,7 1,3 1,2 1,09 -18,6 -18,6
M 25 28 64 0 36 63 5,2 0,8 3 3,04 -18,9 -18,9
F 53 8 38 24 39 67 4,7 0,8 0,6 1,1 -19,4 -19,4
F 65 7 52 39 43 4,8 0,7 0,9 0,9 -19,4 -19,4
F 39 27 79 17 21 4 0,9 0,7 0,93 -19,6 -19,6
F 57 12 86 25 37 68 4,7 0,9 0,8 1,4 -19,9 -19,9
E/A ratio ratio between early (E) and late (A) filling velocity, measured at the mitral valve; F female; FS fractional shortening; GLS global longitudinal
end-systolic strain; GRS global radial end-systolic strain; LVPWd diastolic left ventricular posterior wall thickness; M male; NMDAS newcastle
mitochondrial disease adult scale; UEC urinary epithelial cells; * Kocabay reference values (95%CI); # Kuznetsova reference values (90 % CI)
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collected as part of clinical care are used, 2DSTE seems a
promising method to reliably quantify the abnormal longitu-
dinal myocardial deformation (strain) observed in many
m.3243A>G carriers with a wide spectrum of clinical disease
severity. For this reason, it could be considered as an outcome
measure in future clinical trials. Strain analysis was feasible in
90 % of the patients and 94 % of the images for global longi-
tudinal strain (GLS). Radial and circumferential strain were
not further processed because of a low number of high-quality
images and suboptimal tracking even in high-quality images,
which is in line with the current debate on the reproducibility
of radial strain (Koopman et al. 2010). Decreased GLS was
found in more than half of the m.3243A>G carriers; none of
the carriers had a higher GLS than the average of the age-
matched reference group. In most of the carriers with abnor-
mal strain, cardiac dimensions were also abnormal, whereas
the systolic function was still intact (Supplementary Table 1).
Inter- and intra-rater reliability was good, with a mean differ-
ence of 0.83 for inter and 0.40 for intra-rater reproducibility.
Since our centre has no experience in tagged cMRI, we could
not confirm the very strong correlation between cMRI and
2DSTE for this specific indication.
A previous study showed that myocardial deformation,
measured by cMRI, in m.3243A>G mutation carriers without
known clinical cardiac involvement showed abnormal longi-
tudinal shortening, whereas radial and circumferential strain
were comparable to matched healthy controls (Bates et al.
2013a, b). This is in line with studies in other populations
where GLS by echocardiography is reported to be the most
sensitive strain parameter to assess systolic dysfunction
(Nakai et al. 2009; Nesbitt et al. 2009). Global longitudinal
strain is therefore accepted as a major outcome parameter of,
e.g. chemotherapy related cardiac dysfunction (Plana et al.
2014). In general, GLS is reported to be relatively easy to
measure and more consistent and reproducible compared to
GCS (Kocabay et al. 2014). The hypothesis is that GLS is
affected at first because the longitudinally orientated sub-
endocardial fibres are most susceptible to injury (Nesbitt
et al. 2009). In our present study, we found no correlation
between the longitudinal myocardial deformation and the clin-
ical parameters or clinical scoring such as the NMDAS. This
might be attributed to the relatively small cohort, including
both symptomatic and asymptomatic carries and the heteroge-
neous distribution of heteroplasmy percentages between tis-
sues. Nevertheless, one should keep in mind that mild mito-
chondrial disease may be associated with severe cardiomyop-
athy and therefore all carriers of the m.3243A>G mutation
should be screened for any sign of (subclinical)
cardiomyopathy.
In another follow-up study of m.3243A>G carriers, cMRI
was used to monitor cardiac adaptations and safety of endur-
ance training. No difference was found in GCS during follow-
up; however, GLS was not assessed (Bates et al. 2013a, b).
Other studies report good responsiveness of radial (and in
lesser extent of longitudinal) strain (Weidemann et al. 2003),
and improvement of longitudinal strain under treatment
(Faber et al. 2011) while others report no changes in myocar-
dial strain during the follow-up of patients with progressive
(not mitochondrial) diseases (St John Sutton et al. 2014). In
the present pilot study, we found changes in GLS exceeding
the inter- and intra-observer variability in 39 % of our cohort.
Since we were not able to measure the disease progression
with other methods than 2DSTE itself, one can not rule out
that these changes in GLS could still partly represent the
Fig. 3 Correlation between
heteroplasmy percentages and
GLS. GLS correlates significantly
to the heteroplasmy percentage in
UEC r = 0.45, P = 0.05, but not to
heteroplasmy percentage in
leucocytes (r = −0.17, P = 0.36).
GLS = global longitudinal strain;
UEC = Urinary epithelial cells
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influence of other factors, e.g. changes in medication, or treat-
ment of the most common cause of cardiac hypertrophy: hy-
pertension. The influence of covariates of diminished myocar-
dial deformation, including the decreased myocardial
functioning associated with physiological aging (Cheng
et al. 2010) and with the presence of diabetes mellitus
(Ernande et al. 2010), was not significant in our cohort. This
is probably caused by the high number of young subjects with
Table 4 Clinical and strain parameters during follow-up in
m.3243A>G carriers. Description of the change during follow-up and
the change in global end-systolic strain in longitudinal direction at base-
line and during follow-up in m.3243A>G carriers (n = 21). Time between
echocardiograms, subjective change in exercise tolerance and changes in
medication are also depicted. Red marking indicates a ≥ 10 % increase in
myocardial strain; green marks a ≥ 10 % decrease in myocardial strain
during follow-up
GLS global longitudinal end-systolic strain
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severe m.3243A>G associated cardiomyopathy included in
our cohort and the lack of correlation between the presence
of m.3243A>G associated cardiomyopathy and m.3243A>G
associated symptoms in general (including m.3243A>G asso-
ciated diabetes mellitus). Although we found a moderate cor-
relation between GLS and the heteroplasmy percentage mea-
sured in urinary epithelial cells, the heteroplasmy percentages
in these tissues do not always represent the heteroplasmy per-
centage measured in cardiac muscle, since the m.3243A>G
mutation is distributed unevenly across tissues (Majamaa-
Voltti et al. 2008). Since all studies performed so far are quite
small, larger studies need to be executed to be more conclu-
sive about the discrepancy between our findings and other
observations in small cohorts of mitochondrial patients
(Bates et al. 2013a, b). These studies should spare no effort
to measure systolic function, to confirm that abnormal strain
indeed precedes abnormal ejection fraction and is therefore an
earlier sign of myocardial dysfunction. These studies should
also study the value of 2DSTE in risk stratification or risk
prediction of cardiomyopathy in m.3243A>G carriers.
The analysis of myocardial deformation using tagged
cMRI is considered the reference standard for measuringmyo-
cardial deformation (Tee et al. 2013), yet the lack of availabil-
ity and expertise in many centres hampers its use in future
clinical trials. Although 2DSTE is dependent on operator ex-
perience, machine settings and the acoustic window for trans-
ducer placement of the patient (Tee et al. 2013), the technique
is recently often used in multi-centre clinical trials. Pitfalls of
the 2DSTEmethod itself include its dependency on high qual-
ity images with sufficient frame rate and the limited standard-
ization between vendors. Weaknesses of this pilot study in-
clude the data gathering as part of clinical care, the relatively
small number of carriers of whom two echocardiograms were
available for further 2DSTE, and the lack of standardized
follow-up protocol to allow firm conclusions about the re-
sponsiveness of 2DSTE. Despite the fact that the 2D images
were obtained as part of clinical care, the proportion of high
quality images on which analysis was feasible was compara-
ble to the literature (Stoodley et al. 2011).
More and more trials are performed in patients with mito-
chondrial disease. There is an urgent need for robust outcome
measures (Pfeffer et al. 2013). The wide availability, the non-
invasive nature and independence of voluntary effort of
2DSTE makes it promising as an objective and quantitative
end point for clinical trials. The data for this retrospective pilot
study were collected as part of routine care (using a standard-
ized imaging protocol) and only 77 % of the patients were
suitable for the assessment of longitudinal myocardial strain
using 2DSTE. An important limitation of our study is that
ejection fraction could only be calculated in a small number
of patients. The discrepancy between the feasibility of the
calculation of ejection fraction and the calculation of global
longitudinal strain might be explained by the different images
used for both techniques (4–6 segments of the 4-CV (2DSTE)
versus all segments of both the 2-CVand the 4-CV (EF)), and
by the fact that both parameters were assessed by different
experts teams. Since these numbers are probably higher in
highly standardized prospective studies, we recommend test-
ing the feasibility and responsiveness of GLS in more detail in
a prospective study. Myocardial deformation reflects not only
the myocardial contractility, but probably also global forces
such as pre- and afterload (Nesbitt et al. 2009). For proper use
in future clinical trials, we suggest standardization of, e.g.
medicat ions and fluid intake at the t ime of the
echocardiography.
Given the high prevalence of cardiac abnormalities and the
lack of clear clinical predictors for the presence of not-yet-
symptomatic cardiomyopathy, screening for this condition
might be of major importance. Whether early detection of
myocardial dysfunction in these patients will be beneficial
for the long term prognosis in this population, remains to be
further clarified. Although myocardial deformation seems to
be predictive of heart failure (Choi et al. 2013) and all-cause
mortality (Kalam et al. 2014), the value of treating subtle
subclinical changes in myocardial deformation, detected using
2DSTE, should be studied prospectively in a larger cohort of
adult m.3243A>G carriers.
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